Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hormone-sensitive cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    54 result(s) found for: Hormone-sensitive cancer. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-003591-38 Sponsor Protocol Number: D4200C00045 Start Date*: 2005-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of ZD6474 in combination with Arimidex vs. Arimidex alone in patients with hormone sensitive (ER+ve ...
    Medical condition: Hormone sensitive (ER+ve and/ or PR +ve) advanced breast cancer (ABC)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended) HU (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004412-55 Sponsor Protocol Number: C.HO.SE. Start Date*: 2013-04-15
    Sponsor Name:AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO
    Full Title: Cabazitaxel in relapsed high-risk HOrmone-SEnsitive prostate cancer patients. A multicentric Randomized phase II study. C.HO.SE. Trial
    Medical condition: Relapsed high-risk hormone-sensitive prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000076-37 Sponsor Protocol Number: NL72585.091.20 Start Date*: 2023-03-30
    Sponsor Name:Radboud University Medical Center
    Full Title: Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.
    Medical condition: Oligo-metastatic adenocarcinoma of the prostate.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CY (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003869-28 Sponsor Protocol Number: 9785-CL-0335 Start Date*: 2016-08-04
    Sponsor Name:Astellas Pharma Global Development, Inc (APGD)
    Full Title: ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients ...
    Medical condition: Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing) BE (Completed) ES (Restarted) DK (Completed) FI (Completed) SE (Completed) DE (Completed) SK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000082-41 Sponsor Protocol Number: 2021-0486 Start Date*: 2022-03-31
    Sponsor Name:Fundación para la Investigación en Urología
    Full Title: Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial
    Medical condition: We propose a multicenter, prospective, randomized, single-blind clinical trial, without conflict of interest, to determine the clinical benefit of statins (Pitavastatin 2 mg) in prostate cancer pa...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000346-33 Sponsor Protocol Number: D361BC00001 Start Date*: 2020-07-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients with DeNovo Metastatic Ho...
    Medical condition: Metastatic Hormone-Sensitive Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) SK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002590-38 Sponsor Protocol Number: 17777 Start Date*: 2016-12-14
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, placebo-controlled Phase III study of darolutamide (ODM-201) versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastati...
    Medical condition: Metastatic hormone-sensitive prostate cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) BE (Completed) ES (Completed) FI (Completed) DE (Completed) CZ (Completed) NL (Completed) PL (Completed) FR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001269-10 Sponsor Protocol Number: Doc-Pred Start Date*: 2016-07-14
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: A pharmacokinetic study of Docetaxel and Prednisone in men with metastatic castration-resistant or hormone-sensitive prostate cancer.
    Medical condition: Metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004665-10 Sponsor Protocol Number: GIADA-CA209-959 Start Date*: 2017-06-27
    Sponsor Name:DIPARTIMENTO SCIENZE CHIRURGICHE, ONCOLOGICHE E GASTROENTEROLOGICHE (DISCOG) - UNIVERSITA' DI PADOVA
    Full Title: THE GIADA TRIAL. ENGAGING THE IMMUNE SYSTEM TO IMPROVE THE EFFICACY OF NEOADJUVANT CHEMO-ENDOCRINE THERAPY FOR PREMENOPAUSAL LUMINAL B BREAST CANCER PATIENTS.
    Medical condition: Hormone-sensitive, HER-negative, Luminal B, premenopausal Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070577 Oestrogen receptor positive breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003633-41 Sponsor Protocol Number: MK-3475-991 Start Date*: 2020-03-17
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate ...
    Medical condition: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IE (Trial now transitioned) FI (Completed) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) ES (Completed) AT (Prematurely Ended) NL (Completed) PL (Trial now transitioned) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004991-16 Sponsor Protocol Number: tba Start Date*: 2022-09-28
    Sponsor Name:
    Full Title: 177Lu-PSMA RADIOLIGAND THERAPY IN PATIENTS WITH LYMPH NODE METASTATIC HORMONE-SENSITIVE PROSTATE CANCER UNDERGOING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE D...
    Medical condition: prostate cancer, eligible for radical prostatectomy and extended pelvic lymph node dissection, with 1-3 pelvic nodal metastases on preoperative PSMA PET
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005018-76 Sponsor Protocol Number: S60857 Start Date*: 2019-01-14
    Sponsor Name:University Hospitals Leuven
    Full Title: An open-label, single arm, prospective, multi-center, tandem two stage designed, phase II study to evaluate the efficacy of Fulvestrant in women with recurrent/metastatic estrogen receptor positive...
    Medical condition: endometrial stromal sarcoma uterine adenosarcoma endometrial carcinoma sex cord stromal tumors serous ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000305-21 Sponsor Protocol Number: ASCB-Onco-2336-2017 Start Date*: 2017-10-20
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospectic, phase II, randomized, ...
    Medical condition: prostate cancer with hormone sensitive metastatic bone disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036927 Prostate neoplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000209-10 Sponsor Protocol Number: D8731C00002 Start Date*: 2020-10-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progr...
    Medical condition: Progressive Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000735-32 Sponsor Protocol Number: 56021927PCR3002 Start Date*: 2015-09-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    Medical condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) ES (Ongoing) CZ (Trial now transitioned) PL (Completed) RO (Trial now transitioned) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000943-30 Sponsor Protocol Number: SOGUG-2019-IEC(PRO)-4 Start Date*: 2022-01-12
    Sponsor Name:SOGUG (Spanish Genitourinary Oncologic Group)
    Full Title: Randomized phase II study evaluating the clinical utility of switching from prednisone to dexamethasone after initial biochemical progression in patients with hormone-sensitive metastatic prostate ...
    Medical condition: metastatic prostate cancer hormone sensitive
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003190-96 Sponsor Protocol Number: SHR-3680-III-HSPC Start Date*: 2020-02-10
    Sponsor Name:Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Full Title: One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensiti...
    Medical condition: Metastatic hormone-sensitive prostate cancer with high tumor load
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002350-78 Sponsor Protocol Number: ProBio Start Date*: 2018-10-22
    Sponsor Name:Karolinska Institutet
    Full Title: ProBio: An outcome adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer
    Medical condition: Patients with metastatic hormone-sensitive and castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004008-71 Sponsor Protocol Number: ELDORADO Start Date*: 2017-01-19
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with estrogen receptor positive breast cancer ‘the ELDORADO study’
    Medical condition: Estrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002957-46 Sponsor Protocol Number: 56021927PCR3015 Start Date*: 2020-05-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with Hormone-Sensitive Pr...
    Medical condition: High risk recurrent prostate cancer previously treated with radical prostatectomy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 21 14:06:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA